Clinical Trial Update: A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial evaluating Nipocalimab in children aged 2 to under 18 with generalized Myasthenia Gravis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• Nipocalimab (nipocalimab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Myasthenia Gravis | Phase 2, Phase 3 | Status: RECRUITING